Search
Tachyarrhythmia caused by catecholamine excess
go.drugbank.com/conditions/DBCOND0021765Drugs: PropranololSynonyms: Tachyarrhythmia caused by catecholamine excessTagraxofusp
go.drugbank.com/drugs/DB14731ApprovedInvestigational[A253762] It was also approved by the European Commission on January 7, 2021.[L43712]
Olanzapine
go.drugbank.com/drugs/DB00334ApprovedInvestigationalOlanzapine is a thienobenzodiazepine derivative and an atypical or second-generation antipsychotic agent. Its chemical structure contains a thieno[2,3-b][1,5]benzodiazepine core, and has a methyl group attached to the piperazine ring. Th...
Products: Olanzapine Glenmark EuropeDextropropoxyphene
go.drugbank.com/drugs/DB00647ApprovedIllicitWithdrawnDue to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States.
Inotuzumab ozogamicin
go.drugbank.com/drugs/DB05889ApprovedInvestigational[A20352] Inotuzumab ozogamicin was first approved by the European Commission in June 2017 for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). … [A20352] The antibody portion of the drug binds to CD22 receptors expressed on leukemic B cells and intracellularly releases N-acetyl-gamma-calicheamicin dimethylhydrazide, which produces cytotoxic effects
Dibotermin alfa
go.drugbank.com/drugs/DB11639ApprovedInvestigationalThrough enhancing osteogenesis at the site of implantation, dibotermin alfa accelerates the healing of open tibial shaft fractures and reduces the need for secondary intervention [A31945]. … In a prospective clinical study of patients with an open tibial fracture, administration of dibotermin alfa resulted in faster fracture- or wound-healing, significantly fewer secondary invasive interventions
Carteolol
go.drugbank.com/drugs/DB00521ApprovedA beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.
Risankizumab
go.drugbank.com/drugs/DB14762ApprovedInvestigational[L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019.
Denileukin diftitox
go.drugbank.com/drugs/DB00004ApprovedInvestigationalDenileukin diftitox is an IL2-receptor-directed cytotoxin, is a recombinant DNA-derived fusion protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met1-Thr387)-His and the sequence for human interleukin-2...